Venus Remedies Ltd announces successful receipt of new marketing authorization for DOCETAXEL and GEMCITABINE

Venus Remedies Limited has announced the successful receipt of new marketing authorizations for DOCETAXEL in concentrations of 160MG/8ML, 20MG/1 ML and 80MG/4ML(SingleVlal), as well as GEMCITABINE 1G from Malta, Europe. These approvals signify the commitment to expanding its pharmaceutical portfolio and market presence. The company looks forward to leveraging these authorizations to enhance its global reach and contribute to the advancement of healthcare solutions.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 409.50 as compared to the previous close of Rs. 409.60. The total number of shares traded during the day was 29958 in over 1975 trades.

The stock hit an intraday high of Rs. 429.50 and intraday low of 406.95. The net turnover during the day was Rs. 12600455.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 MarketingAuthorization DOCETAXEL GEMCITABINE